Minimal residual disease (MRD) detection using a tumour naive circulating tumour DNA (ctDNA) assay in patients (pts) with resected colorectal cancer (CRC) in the phase III ASCOLT trial

被引：0

作者：

Day, D. ^{[1
,2
]}

Starus, A. ^{[3
]}

Gebski, V. ^{[4
]}

Simes, J. ^{[4
]}

Hayes, T. ^{[5
]}

Padinharakam, S. ^{[6
]}

Strickland, A. H. ^{[1
,2
]}

Briscoe, K. ^{[7
]}

Varma, S. ^{[8
]}

Barnet, M. ^{[9
]}

Jackson, C. ^{[10
]}

Horvath, L. G. ^{[11
]}

Price, T. J. ^{[12
,13
]}

Tebbutt, N. ^{[14
]}

Karki, B. ^{[15
]}

Diakos, C. I. ^{[16
]}

Chia, J. ^{[17
]}

Toh, H. C. ^{[17
]}

Jones, F. S. ^{[3
]}

Segelov, E. ^{[18
]}

机构：

[1] Monash Hlth, Dept Oncol, Clayton, Vic, Australia

[2] Dept Med, Clayton, Vic, Australia

[3] Sysmex Inost Inc, Med Affairs, Baltimore, MD USA

[4] Univ Sydney, NHMRC Clin Trial Ctr, Sydney, NSW, Australia

[5] Southwest Oncol, Med Oncol, Warrnambool, Vic, Australia

[6] Launceston Gen Hosp, Specialist Care Australia, Launceston, NSW, Australia

[7] Mid North Coast Canc Inst, Med Oncol, Coffs Harbour, NSW, Australia

[8] Townsville Hosp, Dept Oncol, Douglas, Qld, Australia

[9] St Vincents Hosp, Kinghorn Canc Ctr, Sydney, NSW, Australia

[10] Dunedin Publ Hosp, Dept Med Oncol, Dunedin, New Zealand

[11] Chris OBrien Lifehouse, Med Oncol, Camperdown, NSW, Australia

[12] Univ Adelaide, Med Oncol, Adelaide, SA, Australia

[13] Lyell McEwin Hosp, Elizabeth Vale, SA, Australia

[14] Austin Hlth, Dept Oncol, Heidelberg, Vic, Australia

[15] Toowoomba Gen Hosp, Toowoomba Hosp Canc Ctr Serv, Clayton, Vic, Australia

[16] Genesis Care North Shore, Dept Med Oncol, St Leonards, NSW, Australia

[17] NCCS, Dept Med Oncol, Singapore, Singapore

[18] Univ Bern, Dept Clin Res, Fac Med, Bern, Switzerland

来源：

ANNALS OF ONCOLOGY | 2023年 / 34卷

关键词：

D O I：

10.1016/j.annonc.2023.09.1777

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

586P

引用

页码：S426 / S427

页数：2

共 50 条

[1] Tumour naive circulating tumour DNA (ctDNA) analysis in patients (pts) with resected colorectal cancer (CRC) in the phase III ASCOLT trial
Day, D.
Starus, A.
Lamik, A.
Sieber, O.
Begbie, S.
Bonaventura, A.
Rai, S.
Karanth, N.
Underhill, C. R.
Nott, L. M.
Van Hazel, G.
Van Hagen, T.
Wong, M.
Saqib, A.
Eastgate, M.
Srivastav, R.
Chia, J.
Toh, H. C.
Jones, F.
Segelov, E.
[J]. ANNALS OF ONCOLOGY, 2022, 33 (07) : S710 - S710
[2] Circulating-tumour DNA (ctDNA) detection using an ultra-sensitive next generation sequencing (NGS)-based assay in patients with resected colorectal cancer (CRC) in the phase III ASCOLT trial
Day, Daphne
Starus, Anna
Sieber, Oliver
Prasse, Daniela
Lamik, Agathe
Fredebohm, Johannes
Simes, John
Day, Fiona
Jeffery, Mark
Zielinski, Robert
Singh, Madhu
Chong, Geoffrey
Shan, Li
Mouradov, Dmitri
Chia, John W. K.
Ali, Raghib
Toh, Han Chong
Jones, Frederick
Segelov, Eva
[J]. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2022, 18 : 120 - 121
[3] Circulating-tumour DNA (ctDNA) detection using an ultra-sensitive next generation sequencing (NGS)-based assay in patients with resected colorectal cancer (CRC) in the phase III ASCOLT trial
Day, D.
Starus, A.
Sieber, O.
Prasse, D.
Lamik, A.
Fredebohm, J.
Simes, J.
Day, F.
Jeffery, M.
Zielinski, R.
Singh, M.
Chong, G.
Li, S.
Mouradov, D.
Chia, J.
Ali, R.
Toh, H.
Jones, F.
Segelov, E.
[J]. ANNALS OF ONCOLOGY, 2022, 33 : S282 - S283
[4] Minimal residual disease (MRD) detection in colorectal cancer (CRC) using a plasma-only integrated genomic and epigenomic circulating tumor DNA (ctDNA) assay
Parikh, A.
van Seventer, E.
Boland, G.
Siravegna, G.
Hartwig, A.
Jaimovich, A.
Raymond, V. M.
Talasaz, A.
Corcoran, R. B.
[J]. ANNALS OF ONCOLOGY, 2020, 31 : S419 - S419
[5] Personalized circulating tumour DNA assay for the detection of minimal residual disease in CRC patients after resection of metastases
Loupakis, F.
Derouazi, M.
Murgioni, S.
Rizzato, M. D.
Sharma, S.
Renner, D.
Shchegrova, S.
Sethi, H.
Zimmermann, B.
Aleshin, A.
Schirripa, M.
Munari, G.
Dei Tos, A. P.
Lonardi, S.
Fassan, M.
[J]. ANNALS OF ONCOLOGY, 2020, 31 : S413 - S413
[6] Clinical experience of a personalized and tumour-informed circulating tumour DNA assay for minimal residual disease detection in oligometastatic colorectal cancer patients
Cohen, S. A.
Hook, N.
Krinshpun, S.
Westbrook, L.
Loranger, K.
Wallace, J.
Sharma, S.
Aleshin, A.
Billings, P.
[J]. ANNALS OF ONCOLOGY, 2020, 31 : S1274 - S1274
[7] Optimising longitudinal plasma-only circulating tumour DNA (ctDNA) for minimal residual disease (MRD) detection with combined genomic/methylation signals to predict recurrence in patients (pts) with resected stage I-III colorectal cancer (CRC) in the UK multicentre prospective study TRACC.
Slater, Susanna
Bryant, Annette
Aresu, Maria
Begum, Ruwaida
Chen, Hsiang-Chi
Peckitt, Clare
Lazaro-Alcausi, Retchel
Carter, Paul
Anandappa, Gayathri
Khakoo, Shelize
Branagan, Graham
George, Nicol
Abulafi, Muti
Duff, Sarah
West, Nicholas
Bucheit, Leslie
Rich, Thereasa A.
Chau, Ian
Starling, Naureen
Cunningham, David
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 169 - 169
[8] Minimal residual disease detection and tracking tumour evolution using ctDNA in stage I-III colorectal cancer patients
Henriksen, T. V.
Tarazona, N.
Reinert, T.
Carbonell-Asins, J. A.
Roda, D.
Huerta, M.
Rosello, S.
Madsen, A. H.
Iversen, L. H.
Gotschalck, K. A.
Sharma, S.
Wu, H-T.
Shchegrova, S.
Tin, A.
Sethi, H.
Zimmermann, B.
Aleshin, A.
Andersen, C. L.
Cervantes, A.
[J]. ANNALS OF ONCOLOGY, 2020, 31 : S419 - S420
[9] Finding Waldo: The Evolving Paradigm of Circulating Tumor DNA (ctDNA)-Guided Minimal Residual Disease (MRD) Assessment in Colorectal Cancer (CRC)
Chakrabarti, Sakti
Kasi, Anup Kumar
Parikh, Aparna R.
Mahipal, Amit
[J]. CANCERS, 2022, 14 (13)
[10] Bespoke circulating tumour DNA assay for the detection of minimal residual disease in esophageal adenocarcinoma patients
Ococks, E.
Ng, A.
Devonshire, G.
Dashner, S.
Chan, W-C.
Sharma, S.
Wu, H-T.
Redmond, A.
Northrop, A.
Grehan, N.
Sethi, H.
Zimmermann, B.
Smyth, E.
Aleshin, A.
Fitzgerald, R.
[J]. ANNALS OF ONCOLOGY, 2020, 31 : S1317 - S1318

← 1 2 3 4 5 →